Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;4:PO.19.00261. doi: 10.1200/PO.19.00261

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Amount of cell free DNA (cfDNA) and circulating tumor DNA (ctDNA). (A) Comparison of amount cfDNA (measured by albumin [ALB] or β-actin [ACTB]) between patients with neuroblastoma and healthy control donors. (B) Amount of cfDNA (measured by ALB or ACTB) at different time points during treatment. (C) Amount of cfDNA in samples with ctDNA compared with samples from healthy control donors and samples without ctDNA detected. (D) Amount of ctDNA (measured by hypermethylated RASSF1A [RASSF1Am]) at different time points during treatment. Begin induction indicates until 2 courses of induction therapy; mid-induction indicates after 3-5 courses of induction chemotherapy, unless additional courses were given after 6 courses, and samples before last course were also included at this time point; end induction indicates at the end of induction therapy; surveillance indicates during follow-up or at relapse suspicion; and event indicates relapse or progression. HR, high risk; PNQ, positive not quantifiable; PQ, positive and quantified. (*) P < .05, (**) P < .01, (***) P < .001, (****) P < .0001.